BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  FDA

  FDA Greenlights Roche’s Polivy in First-Line DLBCL

  Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone.

  April 20, 2023

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Tubulis and BMS Team Up to Develop Antibody-Drug Conjugates for Cancer

  The deal could be worth more than $1 billion, starting with an upfront payment of $22.75 million.

  April 20, 2023

   · 

  3 min read

   · 

  Alejandra Manjarrez
• 

  Drug Development

  BeiGene’s Tislelizumab Garners Another Phase III Win but Still Awaits Approval in US

  The checkpoint inhibitor is approved for several cancers in China, but after an indefinite FDA delay last summer, BeiGene’s partner Novartis still awaits its first U.S. approval.

  April 20, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution

  Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.

  April 20, 2023

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Business

  Abdera Debuts with $142M to Develop Precision Radiopharmaceuticals

  Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.

  April 20, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Drug Development

  BioInvent Announces a Fourth Complete Response in Phase 1/2 Trial with BI-1206 in Non-Hodgkin’s Lymphoma

  BioInvent International AB announces that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma.

  April 20, 2023

   · 

  4 min read
• Biotech Bay

  Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

  Tubulis and Bristol Myers Squibb announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates.

  April 20, 2023

   · 

  3 min read
• Invitation to a Presentation of the Results from Promore Pharma’s Clinical Trial PHSU05

  Promore Pharma In the light of the publication of the results from the clinical trial PHSU05, Promore Pharma AB invites to a webcast on Friday 21 April kl 10.00

  April 20, 2023

   · 

  1 min read
• BioMidwest

  Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

  Enveda Biosciences announced that it has closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022.

  April 20, 2023

   · 

  3 min read
• Business

  Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023

  Karuna Therapeutics, Inc. announced that it will host a live conference call and webcast on Thursday, May 4, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and provide a general business update.

  April 20, 2023

   · 

  1 min read